Features

Moderate growth is projected for global excipient market overall, but how does that growth break down by functionality, excipient type, and key geographic segments. DCAT Value Chain Insights takes an inside look.

Novo Nordisk and Lilly are leading the charge in the high-growth obesity drug market with their blockbuster drugs recording multi-billion sales growth in the first half of 2024, a trajectory expected to continue for the full year 2024. What are leading drug candidates from other bio/pharma majors?

This coming November, the Drug Supply Chain Security Act is reaching the end of a 10-year implementation plan to achieve an interoperable and electronic way to identify and trace certain prescription drugs at the package level as they move through the supply chain. What steps are left to do?

What have been the top mergers & acquisitions, announced or completed, among bio/pharma companies thus far in 2024? Deal-making to increase market positions in oncology, including antibody drug conjugates and radiopharmaceuticals, are among the top deals.

FDA plans to establish a Rare Disease Innovation Hub to spur product development and commercialization of rare-disease drugs, which have been a strategic priority for many companies, with overall market growth in the double-digits. Will that growth continue?

Which companies have the highest ranked global supply-chain organizations? Three bio/pharma companies made the cut in the Gartner Group’s annual ranking of the top 25 supply-chain organizations. Who are they. and what does it take to be in the top?

High energy costs and inflationary pressures had a major impact on raw materials supply post-pandemic, but what do key macroeconomic indicators now show? Will the moderate growth and slowing inflation seen in the first half of 2024 continue in the near term?

The European Commission has released results from a pilot study evaluating the supply-chain vulnerabilities of 11 critical medicines, including manufacturing dependencies of APIs from outside the EU. What did the study show, and what is next?

As we move past the mid-way mark in 2024, how has the industry fared with new drug approvals? Is the industry keeping pace with prior years’ innovation levels? What is the mix between small molecules and biologics, and which companies are meeting the mark?

Double-digit growth is projected for the contract market for antibody drug conjugates (ADCs). Increased investment by both large bio/pharma companies and smaller ADC innovators is fueling demand for for high-potency manufacturing and conjugation services. Which companies lead the charge?